Article
Inhibition of FLT3 in AML: a focus on sorafenib.
Bone marrow transplantation - 1 Mar 2017
Antar A, Otrock Z K, El-Cheikh J, Kharfan-Dabaja M A, Battipaglia G, Mahfouz R, Mohty M, Bazarbachi A
Abstract excerpt
FMS-like tyrosine kinase 3 (FLT3) is one of the most commonly mutated genes in AML. FLT3 is mutated in ~30% of patients with AML, either by internal tandem duplications (FLT3-ITD) of the juxta-membrane domain or by a point mutation, usually involving the tyrosine kinase domain. Several FLT3 tyrosine kinase inhibitors are being evaluated in multiple studies aiming at improving outcomes. The most widely used is...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.